+Compare
INCY
Stock ticker:
NASDAQ
AS OF
Jun 23 closing price
Price
$74.78
Change
+$1.03 (+1.40%)
Capitalization
16.34B

INCY Price Prediction, Incyte Corp AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Jun 23, 2022

INCY's RSI Oscillator ascends from oversold territory

The RSI Indicator for INCY moved out of oversold territory on June 15, 2022. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 19 of the 27 cases the stock moved higher. This puts the odds of a move higher at 70%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for INCY just turned positive on June 22, 2022. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Momentum Indicator moved below the 0 level on June 03, 2022. You may want to consider selling the stock, shorting the stock, or exploring put options on INCY as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for INCY entered a downward trend on June 10, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.288) is normal, around the industry mean (24.800). P/E Ratio (17.794) is within average values for comparable stocks, (94.818). Projected Growth (PEG Ratio) (0.638) is also within normal values, averaging (3.614). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (290.018).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

INCY is expected to report earnings to rise 214.71% to 53 cents per share on August 02

Incyte Corp INCY Stock Earnings Reports
Q2'22
Est.
$0.54
Q1'22
Missed
by $0.29
Q4'21
Beat
by $1.98
Q3'21
Beat
by $0.24
Q2'21
Beat
by $0.12
The last earnings report on May 03 showed earnings per share of 17 cents, missing the estimate of 45 cents. With 848.44K shares outstanding, the current market capitalization sits at 16.34B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Global Blood Therapeutics (NASDAQ:GBT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.65B. The market cap for tickers in the group ranges from 2.5K to 244.22B. NONOF holds the highest valuation in this group at 244.22B. The lowest valued company is IMUND at 2.5K.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 10%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was -38%. AMHV experienced the highest price growth at 144%, while ATHA experienced the biggest fall at -66%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -38%. For the same stocks of the Industry, the average monthly volume growth was -54% and the average quarterly volume growth was -65%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 71
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -1 (-100 ... +100)
AI

View a ticker or compare two or three

AI
A.I. Advisor
published General Information

General Information

a developer of drugs

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
1801 Augustine Cut-Off
Phone
+1 302 498-6700
Employees
1773
Web
https://www.incyte.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FPAY1.050.06
+5.71%
FlexShopper
APAM36.170.95
+2.70%
Artisan Partners Asset Management
MBI12.950.32
+2.53%
MBIA
FWONA56.171.37
+2.50%
Liberty Media Corp
HROW6.41-0.02
-0.31%
Harrow Health

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with AGIO. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then AGIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
+1.40%
AGIO - INCY
45%
Loosely correlated
+14.41%
RPRX - INCY
44%
Loosely correlated
+3.11%
MYOV - INCY
44%
Loosely correlated
+5.04%
VRTX - INCY
44%
Loosely correlated
+4.11%
KRTX - INCY
44%
Loosely correlated
+2.71%
More